Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
If a company builds assets at 10.6% a year, faster than its revenue growth rate of 9.1% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Akums Drugs and Pharmaceuticals's average Total Assets Growth Rate was 6.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.60% per year.
During the past 6 years, Akums Drugs and Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 15.80%. The lowest was 6.00%. And the median was 6.50%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Akums Drugs and Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Akums Drugs and Pharmaceuticals Total Assets Related Terms
Akums Drugs and Pharmaceuticals Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals Total Assets Chart
Akums Drugs and Pharmaceuticals Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Total Assets of ₹54,470 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Akums Drugs and Pharmaceuticals and its competitors.
Is Akums Drugs and Pharmaceuticals' Total Assets too high?
Akums Drugs and Pharmaceuticals' current Total Assets is ₹54,470 Mil. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Total Assets compare to ZTS?
Akums Drugs and Pharmaceuticals' Total Assets of ₹54,470 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Akums Drugs and Pharmaceuticals and its competitors. Akums Drugs and Pharmaceuticals's current Total Assets is ₹54,470 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Total Assets of ₹54,470 Mil. The current Total Assets is ₹54,470 Mil. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Total Assets is ₹54,470 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score
Get the complete analysis for NSE:AKUMS
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
